drugset
Drugs / Live attenuated influenza vaccine (LAIV4)
last change Dec 2023 re-read 3 minutes ago

Live attenuated influenza vaccine (LAIV4)

Vaccine

Developed for
influenza
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · National Institutes of Health (NIH) · Stanford University

Trials 1

today NCT03898986 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03898986 Oct 2019 → Dec 2023 influenza Stanford University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Live attenuated influenza vaccine (LAIV4) ClinicalTrials.gov intervention name — accepted as the source's own label NCT03898986 ↗
Modality Vaccine “live attenuated influenza vaccine (LAIV)” NCT03898986 ↗
Route Intranasal “The vaccine will be administered as an intranasal spray.” NCT03898986 ↗